Thymosin Alpha-1 Protocol
Dosing & Research
Last Updated: April 22, 2026
Antiviral and immunomodulation research, Vaccine adjuvant studies, Oncology adjunct research, T-cell activation
Evidence Level
Human Clinical Data Available
Species Studied
Human • Rat • Mouse
Half-Life
~2 Hours
Administration
Subcutaneous
Frequency
2x Weekly
How It Works
- Antiviral and immunomodulation research
- Vaccine adjuvant studies
- Oncology adjunct research
- T-cell activation
Dosing Structure
Dose
1.5 mg
Frequency
2x Weekly
Notes
Dose: 0.8-1.6mg twice weekly. Timing: Morning injection preferred. Inject: Abdomen, thigh (rotate sites). Consistent schedule. Break: 4-6 weeks rest after each 8-12 week cycle.
Example Protocols
Dose: 1.5 mg
Frequency: 2x Weekly
Duration: 6-8 weeks
Off Period: Not listed
Protocol Notes
•
Dose: 0.8-1.6mg twice weekly.
•
Timing: Morning injection preferred.
•
Inject: Abdomen, thigh (rotate sites).
•
Consistent schedule.
•
Break: 4-6 weeks rest after each 8-12 week cycle.
Research & Studies
Loading citations…
- Curated References
- CuratedPubMedPMID 22922255Thymosin alpha-1 for chronic hepatitis B: a systematic review and meta-analysis↗J Viral Hepat · 2012 · Zhao P, Xia N, Li J, et al.humanhepatitismeta-analysisdosing
- CuratedPubMedPMID 32773553Thymosin alpha-1 for severe COVID-19: a randomised controlled trial↗Signal Transduct Target Ther · 2020 · Liu Y, Bhatt DL, Bhatt DL, et al.humanCOVID-19immunedosing
- CuratedPubMedPMID 19121476Thymosin alpha-1 activates innate immunity through toll-like receptor-9↗Eur J Immunol · 2009 · Romani L, Bistoni F, Montagnoli C, et al.mechanisminnate immunityTLR9
Research Feedback
0 approved
For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.
Be the first to submit research feedback for this peptide.
Approved submissions will appear here as aggregated insights.